Sanofi (SNYNF) Cash & Equivalents (2009 - 2026)

Sanofi (SNYNF) has 18 years of Cash & Equivalents data on file, last reported at $6.9 billion in Q1 2026.

• Quarterly Cash & Equivalents fell 11.44% year-over-year to $6.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.9 billion (down 11.44% YoY) and the FY2025 annual result came in at $8.9 billion, up 12.09% from the prior year.
• Cash & Equivalents declined to $6.9 billion in Q1 2026 per SNYNF's latest filing, from $8.9 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $17.4 billion in Q2 2025, with the low at $6.9 billion in Q1 2026.
• Average Cash & Equivalents over 5 years is $9.6 billion, with a median of $8.8 billion recorded in 2023.
• Year-over-year, Cash & Equivalents plunged 37.12% in 2022 and jumped 137.59% in 2025.
• Sanofi's Cash & Equivalents stood at $13.0 billion in 2022, then dropped by 27.88% to $9.4 billion in 2023, then fell by 15.15% to $8.0 billion in 2024, then gained by 12.09% to $8.9 billion in 2025, then dropped by 22.23% to $6.9 billion in 2026.
• Business Quant data shows SNYNF's Cash & Equivalents at $6.9 billion in Q1 2026, $8.9 billion in Q4 2025, and $10.4 billion in Q3 2025.